RPI ID: 2021-070-401

Innovation Summary:
Recombinant E. coli strains and synthetic protein sequence designs are used to produce disordered polypeptides such as spidroins and elastin-like peptides (ELPs). The system leverages genome engineering to suppress basal expression and redirect cellular resources toward target biopolymer synthesis. This approach improves yield and reduces metabolic burden. It is compatible with scalable biomanufacturing platforms. 

Challenges / Opportunities:
Biopolymer production is often constrained by host cell inefficiencies and unintended gene expression. This invention addresses those challenges by optimizing genetic control and expression pathways. It enables cost-effective production of bio-based materials and therapeutic proteins. The method supports sustainable and high-throughput manufacturing.

Key Benefits / Advantages:
✔ Increased biopolymer yield
✔ Reduced metabolic burden
✔ Genome engineering for precision control
✔ Compatible with microbial systems
✔ Scalable for industrial use

Applications:
• Bioplastic manufacturing
• Therapeutic protein production
• Industrial biotechnology

Keywords:
biopolymer production, genome engineering, recombinant expression, synthetic biology, metabolic optimization, biomanufacturing

Intellectual Property:
US application, 18/704718, US12391912B2, 25-Apr-2024